#United States #Elk Grove Village #Orsini #Glaukos #Epioxa

Orsini Partners with Glaukos to Bring Epioxa™ to Market

In an exciting development within the realm of rare disease treatment, Orsini, a prominent leader in pharmacy solutions for uncommon diseases, has announced its collaboration with Glaukos, becoming the sole specialty pharmacy partner for Epioxa™, a pioneering therapy aimed at treating keratoconus. This innovative treatment has recently garnered FDA approval in October 2025, marking a significant advancement in the management of this eye condition.

Understanding Keratoconus

Keratoconus is a progressive eye disorder characterized by the thinning and bulging of the cornea, leading to a cone-like shape. This structural change can distort vision significantly and can result in severe impairment of visual function over time. Symptoms commonly include blurred or distorted vision, heightened sensitivity to light and glare, and frequent changes in prescription glasses. If untreated, keratoconus can lead to visual disability and is a leading cause for corneal transplants within the United States.

Epioxa™: A Revolutionary Treatment

Epioxa™ represents a groundbreaking shift in the treatment paradigm for keratoconus patients. Unlike traditional corneal cross-linking methods that necessitate the removal of the corneal epithelium, Epioxa™ offers a non-invasive approach. This topical, oxygen-enriched therapy is bioactivated by ultraviolet light and is designed to reduce the pain and recovery time associated with previous procedures. As a result, patients can experience meaningful clinical outcomes without the extensive recovery periods typically required.

Orsini's CEO, Brandon Tom, expressed enthusiasm for the partnership, stating, "Orsini has been committed to supporting individuals living with keratoconus for over five years. We are thrilled to partner with Glaukos once more to deliver this innovative treatment to the community. Our focus is on expanding access to cutting-edge therapies and enhancing patient outcomes."

A Commitment to Patient Care

Founded in 1987, Orsini has established itself as a leading provider in the realm of rare diseases and gene therapy solutions. The company works closely with biopharma innovators, healthcare professionals, and payors to facilitate access to advanced treatments for patients suffering from rare diseases. Their services include pharmacy distribution, clinical management, and home infusion services, all tailored to create a seamless connection between patients and necessary therapies.

The high-touch care model employed by Orsini ensures that specialized therapy care teams deliver personalized support to each patient, adhering to their belief that "No Patient is Left Behind™." Their commitment to ethical care and accessibility positions them as frontrunners in rare disease management.

Conclusion

Orsini's collaboration with Glaukos for Epioxa™ serves as a testament to the continuous evolution of treatment options available to patients with keratoconus. By leveraging innovative technologies and therapies, they aim to provide patients with improved access to crucial treatments, ultimately enhancing the quality of life for those affected by this rare disease. As awareness and understanding of keratoconus grow, partnerships like these will be vital in transforming how patients manage their condition and improve their visual futures.